-
1 Comment
Pharmaron Beijing Co., Ltd is currently in a long term uptrend where the price is trading 34.1% above its 200 day moving average.
From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.6.
Pharmaron Beijing Co., Ltd's total revenue sank by 27.0% to $2B since the same quarter in the previous year.
Its net income has dropped by 0.7% to $383M since the same quarter in the previous year.
Finally, its free cash flow grew by 94.5% to $-19M since the same quarter in the previous year.
Based on the above factors, Pharmaron Beijing Co., Ltd gets an overall score of 3/5.
ISIN | CNE100003PG4 |
---|---|
Sector | Healthcare |
Industry | Biotechnology |
Exchange | HK |
CurrencyCode | HKD |
Market Cap | 40B |
---|---|
Beta | 1.08 |
PE Ratio | 12.4 |
Target Price | 20.7899 |
Dividend Yield | 1.7% |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3759.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025